Grifols (NASDAQ:GRFS) Shares Gap Up - What's Next?

Grifols, S.A. (NASDAQ:GRFS - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $9.00, but opened at $9.44. Grifols shares last traded at $9.62, with a volume of 483,885 shares changing hands.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Wall Street Zen upgraded Grifols from a "buy" rating to a "strong-buy" rating in a research report on Monday. JPMorgan Chase & Co. lifted their price objective on Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a research note on Tuesday, June 17th.

Grifols Stock Performance

The company has a quick ratio of 0.97, a current ratio of 2.60 and a debt-to-equity ratio of 1.13. The business has a 50 day moving average of $8.32 and a 200 day moving average of $7.72. The company has a market capitalization of $6.47 billion, a P/E ratio of 8.04, a price-to-earnings-growth ratio of 0.32 and a beta of 0.55.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its holdings in shares of Grifols by 5.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company's stock valued at $247,000 after acquiring an additional 1,657 shares during the period. Raymond James Financial Inc. acquired a new position in Grifols in the fourth quarter valued at approximately $91,000. HighTower Advisors LLC lifted its stake in Grifols by 28.3% during the fourth quarter. HighTower Advisors LLC now owns 17,866 shares of the biotechnology company's stock worth $133,000 after purchasing an additional 3,936 shares in the last quarter. Fore Capital LLC acquired a new stake in shares of Grifols in the fourth quarter valued at $967,000. Finally, Brandes Investment Partners LP lifted its holdings in Grifols by 3.0% during the 4th quarter. Brandes Investment Partners LP now owns 20,496,093 shares of the biotechnology company's stock worth $152,491,000 after buying an additional 592,096 shares during the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.